First Script saw continued decreasing opioid trends across our retail and mail-order programs in 2019, even while overall prescription trends saw a slight upward shift in utilization per claim and cost per claim. Even with these changes, opioids remain the #1 therapeutic class by usage and cost, however, 2019 marked the largest reduction of the last 5 years in the percentage of opioid scripts with greater than or equal to 90 MED. View the video blog here.
More stories
Enlyte
Article
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
Enlyte
Article
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
PDF
Article
Specialty Services Are a Big Deal
When adjusters have to jump through hoops to make referrals, they lose precious time.
Mitchell
Virtual Event
Navigating Michigan’s No-Fault Auto Fee Schedule Four Months In
On-Demand
On July 2, 2021, Michigan’s new auto fee schedule went into effect for services rendered on or after that date.
Enlyte
News Release
Enlyte Family of Companies Publish Inaugural Report Offering Trends and Predictions for Property & Casualty (P&C) and Collision Repair Industries
SAN DIEGO—October 19, 2021—Enlyte, the new parent brand unifying Mitchell, Genex and Coventry, today released its inaugural report
Enlyte
News Release
Mitchell, Genex and Coventry Unite Under a Single, New Brand: Meet Enlyte
SAN DIEGO, CA—October 13, 2021—Mitchell, Genex and Coventry formally announced today the creation of their new parent brand, Enlyt